Table 1 Case-control studies of PKLR rs3020781 and NOS1AP rs7538490 in relation to type 2 diabetes, overweight and obesity
PKLRrs3020781 | |||||||
|---|---|---|---|---|---|---|---|
n (men/women) | TT (%) | TC (%) | CC (%) | MAF (95% CI) | p AF | OR (95% CI) | |
NGT | 4,736 (2,209/2,527) | 2,602 (55) | 1,812 (38) | 322 (7) | 25.9 (25.0–26.8) | 0.49 | 1.02 (0.96–1.10) |
T2D | 3,674 (2,187/1,487) | 1,998 (54) | 1,412 (39) | 264 (7) | 26.4 (25.4–27.4) | ||
BMI < 25 (kg/m 2 ) | 5,036 (2,111/2,925) | 2,732 (54) | 1,952 (39) | 352 (7) | 26.4 (25.5–27.2) | ||
25 ≤ BMI < 30 (kg/m 2 ) | 6,985 (4,359/2,626) | 3,821 (55) | 2,700 (39) | 464 (6) | 26.0 (25.2–26.7) | 0.49 | 0.98 (0.92–1.04) |
BMI ≤ 30 (kg/m 2 ) | 4,780 (2,467/2,313) | 2,612 (55) | 1,845 (38) | 323 (7) | 26.2 (25.3–27.1) | 0.81 | 0.99 (0.93–1.06) |
NOS1AP rs7538490 | |||||||
n (men/women) | CC (%) | CT (%) | TT (%) | MAF (95% CI) | p AF | OR (95% CI) | |
NGT | 4,755 (2,218/2,537) | 2,479 (52) | 1,914 (40) | 362 (8) | 27.7 (26.8–28.7) | 0.84 | 0.99 (0.93–1.06) |
T2D | 3,692 (2,200/1,492) | 1,954 (53) | 1,439 (39) | 299 (8) | 27.6 (26.6–28.6) | ||
BMI < 25 (kg/m 2 ) | 5,064 (2,128/2,936) | 2,635 (52) | 2,013 (40) | 416 (8) | 28.1 (27.2–29.0) | ||
25 ≤ BMI < 30 (kg/m 2 ) | 7,030 (4,384/2,646) | 3,628 (51) | 2,857 (41) | 545 (8) | 28.1 (27.3–28.8) | 0.48 | 0.95 (0.83–1.09) |
BMI ≥ 30 (kg/m 2 ) | 4,819 (2,490/2,329) | 2,517 (52) | 1,923 (40) | 379 (8) | 27.8 (26.9–28.7) | 0.68 | 0.99 (0.93–1.05) |